This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Diqi Pharmaceuticals Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Huafeng Luo: Innovator in Gastro-Retentive Drug Delivery Systems
Introduction
Huafeng Luo is a notable inventor based in Guangdong, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of drug delivery systems. His innovative approach has led to the creation of a unique gastro-retentive sustained-release tablet.
Latest Patents
Huafeng Luo holds 1 patent for his invention titled "Lenalidomide gastro-retentive sustained-release tablet and preparation method thereof." This invention discloses a sustained-release tablet that includes 3 wt % to 14 wt % of lenalidomide, 14 wt % to 68 wt % of a release enhancer with low bulk density, and 23 wt % to 70 wt % of a sustained-release material with low bulk density. The formulation is designed to remain in a floating state within the gastric environment, enhancing drug bioavailability while minimizing side effects.
Career Highlights
Throughout his career, Huafeng Luo has worked with various pharmaceutical companies, including Diqi Pharmaceuticals Co., Ltd. and Guangzhou Diqi Pharmaceuticals Co., Ltd. His work has focused on improving drug formulations and delivery methods, showcasing his commitment to advancing pharmaceutical science.
Collaborations
Huafeng Luo has collaborated with notable professionals in the field, including Feng Liu and Jingyu He. These collaborations have contributed to the development of innovative pharmaceutical solutions.
Conclusion
Huafeng Luo's contributions to the pharmaceutical industry, particularly through his patented gastro-retentive sustained-release tablet, highlight his role as an innovator in drug delivery systems. His work continues to influence the field and improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile